NCT04995614 is a clinical trial of Radium-223 in Castrate Resistant Prostate Cancer, sponsored by Radboud University Medical Center.

Who is sponsoring NCT04995614?

NCT04995614 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04995614?

Interventions in NCT04995614: Radium-223.

What condition does NCT04995614 study?

NCT04995614 studies Castrate Resistant Prostate Cancer, Bone Metastases.

Is NCT04995614 still recruiting?

NCT04995614 is currently completed. Last updated 9 August 2021.

Last reviewed 2021-08-09 · How we verify

NCT04995614

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Completed Last updated 9 August 2021

What this trial tests

trial testing Radium-223 in Castrate Resistant Prostate Cancer in 122 participants. Completed in 29 June 2020.

Timeline

1 April 2017

Primary endpoint
29 June 2020

29 June 2020

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	122
Start date	1 April 2017
Primary completion	29 June 2020
Estimated completion	29 June 2020
Sites	11 locations across Netherlands

Drugs / interventions tested

Radium-223 (radium-223) — full drug profile →

Conditions studied

Castrate Resistant Prostate Cancer — all drugs for Castrate Resistant Prostate Cancer →
Bone Metastases — all drugs for Bone Metastases →

Sponsor

Radboud University Medical Center

Who can join

18 and older, male only, with Castrate Resistant Prostate Cancer or Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in daily practice. Furthermore, the investigators aim to determine patient groups with identical health-related quality of life patterns over time, in order to identify variables related to health-related quality of life deterioration during the course of treatment, as patients with health-related quality of life deterioration may need specific attention to preserve health-related quality of life.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ, Oving IM, Wyndaele DNJ, van Basten JP, et al · · 2023 · cited 8× · PMID 35804188 · DOI 10.1038/s41391-022-00569-8
Optimal assessment of quality of life for patients with prostate cancer.
Briggs LG, Sentana-Lledo D, Lage DE, Trinh QD, et al · · 2022 · cited 7× · PMID 36531831 · DOI 10.1177/17588359221141306
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of <sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al · · 2024 · cited 3× · PMID 38423781 · DOI 10.2967/jnumed.123.266654

Verify or expand the search:

Other trials of Radium-223

Trials testing the same drug.

NCT05924672 — Efficacy of Ra-223 in PSMA PET Optimally Selected Patients · Phase 2 · active not recruiting
NCT05701007 — Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland · completed
NCT05383079 — Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer · Phase 1, PHASE2 · active not recruiting
NCT04206319 — Radium-223 in Biochemically Recurrent Prostate Cancer · Phase 2 · active not recruiting
NCT04109729 — Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer · Phase 1 · active not recruiting

Other recruiting trials for Castrate Resistant Prostate Cancer

Currently open trials in the same condition.

NCT05766371 — Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer · Phase 2 · recruiting
NCT04969315 — TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06783127 — Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04995614 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 9 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04995614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing